Evolus, Inc. (EOLS) Stock Analysis
A live, multi-source view of Evolus, Inc. (EOLS): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Evolus, Inc.
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Sector: Healthcare · Industry: Drug Manufacturers - Specialty & Generic · United States · 353 employees · evolus.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Evolus, Inc. (EOLS) had a market capitalization of $614.3M (forward 33.7) and a beta of 1.43; the shares traded in a 52-week range of $3.86 – $9.31 (18.9% over the year).
- Market cap
- $614.3M
- Enterprise value
- $733.9M
- Forward P/E
- 33.7
- EPS (trailing)
- $-0.54
- EPS (forward)
- $0.28
- Payout ratio
- 0.0%
- 52-week range
- $3.86 – $9.31
- 52-week change
- 18.9%
- Beta
- 1.43
- Average volume
- 898,506
- Shares outstanding
- 66.1M
- Short % of float
- 8.97%
- Profit margin
- -10.8%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-10
In RapidTradeView’s 2026-09-10 scan of the US universe, Evolus, Inc. (EOLS) last closed at $8.57 (the last completed close before that scan).
Technicals at the scan: RSI 55 (neutral territory), price -0.9% versus its 20-day average, 20-day versus 50-day average spread +18.0%, MACD histogram -0.07.
Sentiment inputs: StockTwits 100% bullish; analyst consensus score 75/100.
Next scheduled company event: in 55 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of EOLS; corporate insiders filed 0 buys and 1 sell (1 filer, latest disclosure 2026-09-04). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: David Moatazedi (0B/1S). Who is trading what
RapidTradeView pick record
EOLS has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Evolus, Inc. (EOLS) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell EOLS.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.